Did you mean 10 02 0?
Displaying drugs 1526 - 1550 of 2367 in total
HH-009
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
ALS-08
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
AT-001
AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain Health in Aging).
Investigational
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
AB-001
Investigational
VCN-01
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
OT-004
Investigational
CT-001
Investigational
PF-03758309
PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
CMC 001
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Investigational
XTL-001
XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B virus (HBV).
Investigational
AGS-005
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
Investigational
NV-07a
NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Investigational
MK-0354
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
GS 0573
Investigational
HT-0712
BLX-028914 has been used in trials studying the treatment and basic science of Allergic Rhinitis and Age-Associated Memory Impairment (AAMI).
Investigational
MK-0812
MK0812 has been used in trials studying the treatment of Relapsing-Remitting Multiple Sclerosis.
Investigational
MK-0893
MK0893 has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.
Investigational
MK-0767
MK0767 has been used in trials studying the treatment of Dyslipidemia, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type II, among others.
Investigational
RRx-001
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
Investigational
MK-0873
MK-0873 has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
ONT-093
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
Displaying drugs 1526 - 1550 of 2367 in total